Released Aug 8, 2013, after the close
10-Q filed Aug 8, 2013, 39 days after period end · 0001144204-13-043990
Q2 2013 · 10-Q
Revenue$2.26M$2.26M −91.3% vs Q2 2012−36.5% vs Q1 2013
Net Income-$6.84M-$6.84M N/M vs Q2 2012N/M vs Q1 2013
EPS Diluted-$0.07-$0.07 N/M vs Q2 2012N/M vs Q1 2013
Gross Profit$1,746,000−92.1%
Operating Income-$6,894,000N/M
Operating Cash Flowderived-$8,109,000N/M
Free Cash Flowderived-$8,808,000N/M
Margins · derived
Gross margin77.1%−7.0 pt vs Q2 2012
Operating margin-304.5%−341.3 pt vs Q2 2012
Net margin-302.0%−338.9 pt vs Q2 2012
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2013 | Q2 2012 | Q2 2011 | Q2 2010 |
|---|---|---|---|---|
| Revenue | $2.26M | $26.11M | $764.00K | $1.14M |
| Net Income | -$6.84M | $9.64M | -$13.69M | -$10.04M |
| EPS Diluted | -$0.07 | $0.10 | -$0.16 | $0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR